アミオトロフィック横筋硬化症におけるアンチセンセスオリゴヌクレオチド療法
Gergo Erdi-Krausz1,2, Pamela J Shaw1,2
1Sheffield Institute for Translational Neuroscience, the University of Sheffield.
Current opinion in neurology
|August 20, 2025
まとめ
アンチセンセスオリゴヌクレオチド (ASO) 治療は,アミオトロフィック横筋硬化症 (ALS),特にSOD1-ALSの治療に有望である. 進行中の研究は,他の遺伝子変異と散発性ALSのためにASOを探索し,潜在的に神経変異を逆転させる.
科学分野:
- 神経科学
- 遺伝学
- 薬理学について
背景:
- アミオトロフィック横筋硬化症 (ALS) は致命的な神経変性疾患で,治療の選択肢は限られている.
- SOD1-ALSに対する反感覚オリゴヌクレオチド (ASO) のトフェルセン (tofersen) の最近の承認は,大きな進歩を意味します.
研究 の 目的:
- 様々な形態のALSに対するASO治療の現状と将来の可能性を検討する.
- ASOベースの治療における有望な臨床前および臨床開発を強調する.
主な方法:
- ALSに対するASO療法に関する最近の臨床試験と臨床前研究のレビュー.
- 遺伝的変異 (SOD1,C9orf72) を標的にするASOと,散発性ALSにおける異常スプライシングに焦点を当てます.
- 治療効果を評価するために,患者から得られた細胞および動物モデルを使用する.
主要な成果:
- ASO治療はSOD1-ALSにおいて成功している.
- C9orf72-ALSを標的とした試験は課題に直面しているが,新しい臨床前データは希望をもたらしている.
- 散発性ALSおよびTDP-43病理における異常スプライシングを標的とする有望な臨床前試験結果がある.
結論:
- ASO治療は家族性ALS,特にSOD1-ALSに対する有望な戦略です.
- 他の遺伝的なALS形態と散発的なALSにおけるASOの適用については,さらなる研究が進行中です.
- これらの治療は病気の進行を止め,潜在的に神経変異を逆転させることを目的としています.
関連する概念動画
siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
RNA Interference
26.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.4K
Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375


